Please note that clinical key documents are not designed to be printed, but to be viewed on-line. This is to ensure that the correct and most up to date version is being used. If, in exceptional circumstances, you need to print a copy, please note that the information will only be valid for 24 hours



Hepatitis B and C (PIP)

Key Document code:	WAHT-TP-062	
Key Documents Owner:	Dr Dawson	Consultant Paediatrician
Approved by:	Paediatric Quality Improvement meeting	
Date of Approval:	26 th March 2021	
Date of review:	26 th March 2024	
This is the most current document and should be used until a revised version is		
in place		

The following guidance is taken from the Partners In Paediatrics (PIP)

Please note that clinical key documents are not designed to be printed, but to be viewed on-line. This is to ensure that the correct and most up to date version is being used. If, in exceptional circumstances, you need to print a copy, please note that the information will only be valid for 24 hours



Hepatitis 2018-20

HEPATITIS **B AND C**

Discuss all children with suspected hepatitis B or C with regional liver unit/infectious diseases team for counselling, information, consideration for anti-viral therapy and need for referral

HEPATITIS B

Diagnostic tests

- HBsAg, HBcAb (IgM and IgG) and HBsAb
- If HBsAg +ve then check:
- HBeAg, HBeAb, genotype and HBV DNA PCR viral load
- anti–HDV
- anti-HIV
- anti-HCV
- anti-HAV
- liver function tests including ALT, AST, GGT and albumin
- refer to regional liver unit/infectious diseases team and notify Public Health England
- Serological markers:
- HBsAg: infected
- HBsAb: immune
- HBcAb-IgM: acute infection
- HBcAb-IgG: past infection (>6 months)
- HBeAg: high risk viral replication
- HBeAb: partial sero-conversion
- HBV DNA quantitation: level of virus
- HBV genotype: distribution based on geographical location (subtypes A–G)
 - may be responsible for variations in clinical outcomes and response to antiviral treatment, but not used to determine initial treatment of HBV

Who to screen

- Close contacts of people with confirmed acute and chronic hepatitis B infection
- Migrants from highly endemic areas
- Infants born to hepatitis B positive women when completed vaccination course at aged 12 months

Follow-up of HBsAg +ve children

- HBeAg -ve/HBeAb +ve: yearly
- HBeAg +ve: 6 monthly
- Abnormal liver function tests: 3 monthly

Assessment during follow-up

- Clinical assessment
- Serology (clotted specimen): HBsAg, HBeAg, HBeAb
- Hepatitis B DNA PCR viral load (EDTA)
- LFT (bilirubin, ALT/AST, ALP, albumin)
- GGT
- FBC
- Coagulation (INR, PT, PTT)
- Alpha-fetoprotein
- Abdominal ultrasound every 5 yr
- if family history of hepatocellular carcinoma or rise in alpha-fetoprotein, yearly
- Fibroscan yearly (if available)

Action

• If LFT or alpha-fetoprotein abnormal, or viral titres are rising, inform regional liver unit/infectious diseases team to start antiviral therapy

Please note that clinical key documents are not designed to be printed, but to be viewed on -line. This is to ensure that the correct and most up to date version is being used. If, in exceptional circumstances, you need to print a copy, please note that the information will only be valid for 24 hours



HEPATITIS C

Diagnostic tests

(For neonates see Neonatal guidelines)

- Hepatitis C Virus (HCV) antibody aged >18 months
- HCV PCR if HCV antibody +ve

Who to screen

- Children of women found to be infected with hepatitis C
- Close contacts of people diagnosed with hepatitis C
- Migrants from highly endemic areas

Action

- If HCV Ab -ve, not infected. Discharge
- If HCV Ab +ve and HCV PCR negative in 2 samples taken 6 months apart, not infected (resolved infection or maternal antibody if aged <18 months). Discharge
- If HCV PCR +ve, check genotype, refer to regional liver unit/infectious diseases team for treatment

Yearly follow-up in untreated patients

- Clinical assessment
- HCV PCR viral load (EDTA)
- LFT (bilirubin, ALT/AST, ALP, albumin)
- GGT
- FBC
- Coagulation (INR, PT, PTT)
- Alpha-fetoprotein
- Abdominal ultrasound at diagnosis and every 5 yr
- Fibroscan annually (if available)